The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays

Ann Clin Biochem 2007;44:463-466
doi:10.1258/000456307781646102
© 2007 Association for Clinical Biochemistry

 

This Article
Right arrow

Full Text (PDF)

Right arrow
Alert me when this article is cited
Right arrow
Alert me if a correction is posted
Services
Right arrow
Email this article to a friend
Right arrow

Similar articles in this journal

Right arrow
Similar articles in PubMed
Right arrow
Alert me to new issues of the journal
Right arrow
Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow
Articles by Durham, B. H
Right arrow
Articles by Fraser, W. D
Right arrow Search for Related Content
PubMed
Right arrow
PubMed Citation
Social Bookmarking

What’s this?

Original Articles


Brian H Durham,
Frank Joseph,
Lisa M Bailey and
William D Fraser


Department of Diabetes and Endocrinology, Royal Liverpool University Hospital, Liverpool, UK;
Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Liverpool, UK


Background: The measurement of the serum concentration of fibroblastgrowth factor-23 (FGF-23) is beginning to be used as a diagnostictool in renal phosphate wasting disorders. Having observed anincreased serum FGF-23 in three subjects with low circulatingferritin concentrations we investigated the association betweenlow ferritin and raised serum FGF-23.

Methods: We measured FGF-23 in 150 random anonymized serum samples with ferritin concentrations between <5 and 50 µg/Lusing three commercially available enzyme-linked immunosorbentassay (ELISA) kits. One kit, Human FGF-23[C-term] (ImmutopicsInc, USA) measures total FGF-23 whereas the other two kits,Immutopics intact and FGF-23 ELISA (Kainos, Japan) are reportedto measure only the biologically active intact molecule.

Results: We have detected a significant inverse correlation of -0.565 (P<0.0001) between serum ferritin when <50 µg/Land FGF-23 using the C-terminal assay. This relationship isalso shown with the Immutopics intact assay but is not demonstratedwith the Kainos intact assay.

Conclusion: The measurement of FGF-23 by both Immutopics assaysis altered in the presence of low circulating concentrationsof serum ferritin whereas with the Kainos intact assay thiseffect was not demonstrated. Serum ferritin should be measuredwhen an elevated FGF-23 is obtained using the Immutopics C-terminalor intact FGF-23 assay to prevent misdiagnosis of the causeof this abnormality.


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What’s this?